Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced team with prior success in bringing important new drugs to market. We believe we have the resources, experience and drive to improve the lives of patients and build sustainable value for our shareholders.
WILMINGTON, Del., Feb 25, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) announced today it will present at the
Cowen and Company 30th Annual Health Care Conference on Monday, March 8,
2010 at 3:15 p.m. ET. Presenting for Incyte Corporation will be Paul
Friedman, M.D., president and chief executive officer.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
p...
Two Major Strategic Collaborations EstablishedStrong Year-End Cash Position with 2011 Debt RestructuredSubstantial Clinical Progress AchievedConference Call Scheduled Today at 8:30 a.m. ETWILMINGTON, Del., Feb 18, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq:INCY) today reported fourth quarter and full
year 2009 financial results, provided an update on key fourth quarter
accomplishments and 2010 objectives, and announced its 2010 financial
guidance.
Paul A. Friedma...
WILMINGTON, Del., Feb 09, 2010 (BUSINESS WIRE) -- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled
its fourth quarter and year-end 2009 financial results conference call
for 8:30 a.m. ET on Thursday, February 18, 2010. The schedules for the
press release and conference call are as follows:
Q4 & YE 2009 Press Release:
...
Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Pamela M. Murphy VP, Investor Relations and Corporate Communications Experimental Station Route 141 & Henry Clay Road Building E336 Wilmington, DE 19880 302.498.6944 302.425.2707 pmurphy@incyte.com
